Physician profile
Charis Noteboom
NPI 1831628635
$3,323.15
in general payments reported to CMS, 2019-2025
20 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $43.14 · 2021: $1,078 · 2022: $648 · 2023: $679 · 2024: $447 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.83 | 2019-2025 | |
| Coopersurgical, INC. | $436.68 | 2021-2024 | Paragard T 380a, Endosee |
| Biogen, INC. | $242.21 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $198.96 | 2022-2024 | Twirla |
| Medtronic, INC. | $196.48 | 2021-2023 | Truclear |
| Novo Nordisk INC | $192.12 | 2022-2024 | Wegovy, Saxenda |
| Hologic Sales and Service, LLC | $176.95 | 2021-2025 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $160.16 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $151.99 | 2021-2022 | |
| Astellas Pharma US INC | $147.75 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $143.29 | 2021-2024 | |
| Myovant Sciences INC. | $120.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.53 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $67.91 | 2021-2025 | |
| Momentis Surgical INC. | $60.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $40.84 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.47 | 2023 | Xifaxan, Trulance |
| Stryker Corporation | $16.82 | 2023 | Iris |
| Minerva Surgical, INC | $15.41 | 2024 | |
| Merck Sharp & Dohme LLC | $13.97 | 2024 | Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charis Noteboom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.